The Patent Dance is no longer a dance—it’s a courtroom strategy.
For biologics and biosimilars, the BP(C)IA “dance” used to be viewed as a procedural hurdle: exchange notices, track deadlines, and hope the litigation doesn’t derail launch plans. But …

Big Pharma loves to talk about pipelines. But the real forecasting edge is hiding in the supply chain—specifically in the unglamorous, data-heavy world of drug patents.
Here’s the uncomfortable truth: most “market forecasts” still start with demand ass…

Patent cliffs don’t just threaten revenue—they can quietly reshape your supply chain.
When a blockbuster drug’s exclusivity ends, the market doesn’t simply “get cheaper.” It gets messier: new entrants, shifting manufacturing priorities, changing lead…

Generic drug makers are facing a quiet crisis—and it’s not about demand. It’s about math.
For years, the generic business model has been straightforward: win approvals, secure contracts, scale manufacturing, and harvest steady margins as brand exclusiv…

Branded pharma’s revenue model is under siege—and it’s not just one problem. It’s a stack.
In a recent DrugPatentWatch post, the argument is blunt: the “branded” playbook—win big with a blockbuster, ride exclusivity, then defend share—has been hit from…

Generic drug entry isn’t just about science—it’s about timing.
If you’ve ever wondered how some generic manufacturers seem to “arrive” right when the market opens—often with surprising speed and precision—the answer is hiding in plain sight: the FDA …

Biopharma hiring is broken in a very specific way: we keep treating IP as a silo—when, in reality, IP portfolios are organizational maps.
That’s the core idea behind the DrugPatentWatch piece on “reading the patent” to find the executive—and how IP por…

The “generic cliff” isn’t a cliff at all—it’s a deadline pharma companies engineer around.
For years, the public narrative has been simple: patents expire, generics rush in, revenues fall off a cliff. But anyone watching the industry closely knows th…

Patent thickets are the quiet tax on innovation—and drug companies are getting very good at building them.
If you’ve ever wondered why some biologic “blockbusters” seem to face a wall of legal filings long after the original patent expires, the answe…

AI Prior Art Search: How to Invalidate Key Drug Patents Before You Pay
Most people think patent risk is something you handle after you’ve already committed—after the deal is signed, after the product roadmap is locked, after the money is spent.
That’s …